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CASE REPORT
Primary effusion lymphoma (PEL) is a rare and
newly defined form of non-Hodgkin’s lymphoma
(NHL) which only involves the body cavities, caus-
ing lymphomatous effusions in the absence of
lymphadenopathy or organomegaly.1,2 PEL de-
velops in a serous body cavity such as the pleural,
pericardial and abdominal cavities, and subarach-
noid space.3 Previous studies suggested that PEL
occurs almost exclusively in human immunodefi-
ciency virus (HIV)-infected patients, first described
in association with Kaposi’s sarcoma.1,2 More re-
cently, several studies have demonstrated that
PEL develops in non-AIDS patients with human
herpesvirus type 8 (HHV-8) infection, suggesting
that HHV-8 infection plays a key role in PEL.4
Several reports showed that PEL could occur in
patients with hepatitis C virus (HCV) infection.5,6
We report a case of PEL with underlying hepatitis B
virus (HBV)-related liver cirrhosis.
Case Report
The patient was a 54-year-old man with chronic
hepatitis B for more than 25 years, in whom liver
cirrhosis was diagnosed 3 years ago. He received
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Primary effusion lymphoma (PEL) is an unusual form of non-Hodgkin’s lymphoma, which is character-
ized by lymphomatous effusion in body cavities, but no associated mass lesions. It is usually associated
with an immunodeficient state most often with the human immunodeficiency virus (HIV). We describe a
54-year-old man with HIV-negative PEL, with a history of hepatitis B virus-related liver cirrhosis. Both ab-
dominal and pleural cavities were involved; no solid tumor masses were found and bone marrow investi-
gations were normal. The ascites and pleural effusion contained numerous pleomorphic lymphoid cells.
Immunophenotyping was positive for CD138. Chromosome study showed complex cytogenetics. The ge-
nomic human herpesvirus-8 was detected in the lymphoma cells. It is postulated that the immuno-
suppressed state in this patient may have been caused by cirrhosis. The patient received four cycles of
chemotherapy of CHOP and Picibanil (OK-432) intraperitoneal administration. However, no durable 
remission was achieved. Adefovir failed to halt the progressive liver failure after the development of 
YMDD mutant related to lamivudine. He died of sepsis and hepatic failure. [J Formos Med Assoc 2007;
106(6):504–508]
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lamivudine from December 2000 for elevated
alanine aminotransferase (ALT). Hepatitis B sur-
face antigen (HBsAg) was positive. Hepatitis B e
antigen (HBeAg) was negative, and antibody to
HBeAg (anti-HBeAg) was positive. Antibody to
HCV (anti-HCV) was negative. Lamivudine was
discontinued in June 2001 with persistently nor-
mal ALT and undetectable HBV DNA. Lamivudine
was restarted in January 2002 because of relapse
of hepatitis (ALT, 397 U/L; HBV DNA, 523 pg/mL).
Lamivudine was discontinued in October 2002
after the HBV activity subsided. Again, ALT became
elevated (483 U/L) in March 2003. Lamivudine
was resumed and continued thereafter.
However, progressive abdominal distension
was noted in October 2003 and was aggravated
rapidly in February 2004. He was admitted to our
hospital in March 2004. Body weight increased
from 82 to 92 kg in 5 months. On examination,
the patient was chronically ill-looking. Conscious-
ness was clear. The body temperature was 36.8°C,
pulse rate was 112/minute and respiratory rate was
22/minute. The blood pressure was 130/80mmHg.
The conjunctivae were mildly pale and the scle-
rae were anicteric. The pupils were isocoric with
prompt light reflex. The neck was supple without
lymphadenopathy or jugular vein engorgement.
Breath sounds were clear over bilateral lung fields.
The abdomen was ovoid with shifting dullness.
Neither tenderness nor rebound pain was noted.
The liver was impalpable.
The hemogram showed normocytic anemia
(8.8 g/dL). Biochemistry showed hypoalbumine-
mia (3.2 g/dL), impaired renal function (creati-
nine, 2.0 mg/dL) and high lactate dehydrogenase
level (740 U/L). Other biochemistry data includ-
ing serum ALT and bilirubin level were within
normal limits. The prothrombin time was normal.
Abdominal sonography showed liver cirrhosis
with patent portal vein, mild splenomegaly and
massive ascites. Abdominal magnetic resonance
imaging showed cirrhotic change of the liver with
marked ascites without vascular obstruction.
Paracentesis was performed and 1030 mL bloody
ascites was drained. Cytology of the ascites re-
vealed large and medium sized lymphoid cells with
prominent nucleoli. Some had round vacuoles
in their cytoplasm (Figure 1). The immunophe-
notyping of the lymphoma cells was positive 
for CD138, negative for CD19, cytoplasmic im-
munoglobulin (both κ and λ) and cytoplasmic
CD3. Chromosome study showed complex cyto-
genetics. All of the 13 mitotic cells showed clonal
aberrations including add(1)(q22), −2, +3, +der(4)
t(1;4)(q23;q21), del(4)(q31q35), +5, add(7)(p22),
add(8)(p22), del(8)(q24), add(9)(q32), add(10)
(q26), add(11)(q25), add(11)(q23), add(12)
(q24), +del(13)(q31q34), del(13), +add(14)(q32), 
A B
Figure 1. Cytology of primary effusion lymphoma. (A) The tumor cells in ascites show predominance of large 
lymphocytes exhibiting anisonucleosis, round nuclei, coarse chromatin and increased nuclear and cytoplasmic ratios.
Some round vacuoles are present in the cytoplasm (hematoxylin & eosin stain; original magnification 400×). (B) Tumor
cells in pleural effusion.
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add(14)(q32), der(14)t(14;15)(q24;q22), +15,
der(21)(q10), and add(21)(q22). The cell block of
the ascites showed MuM-1 (−), VS38C (+), EBER
(−). The nuclei of the lymphoma cells were posi-
tive by immunohistochemistry for the HHV-8-
associated latent protein. During admission,
massive pleural effusion developed. Pleural tap-
ping revealed similarly abnormal cells that were
found in the ascites. However, the second abdom-
inal tapping revealed very few lymphoma cells in
the ascites. Instead, the lymphoma cells could be
easily detected in the pleural effusions. Sediments
from the pleural effusions and second ascites were
sent for polymerase chain reaction (PCR) to detect
HHV-8 DNA. Direct sequencing was done to val-
idate the correctness of PCR products. As shown
in Figure 2, HHV-8 DNA could be detected in 
the lymphoma cells of pleural effusions. However,
HHV-8 DNA was not detected in the second 
ascites specimen. We did not perform HHV-8 PCR
in the first ascites sample.
A bone-marrow aspirate and trephine biopsy
showed no evidence of lymphoma involvement.
Computed tomography scan from neck to pelvis
showed no pathologic lymphadenopathy. The re-
sult of exploratory laparoscopy was negative. The
serology of HIV was negative. Based on the cytol-
ogy, immunophenotyping and genetics, PEL was
diagnosed.
The patient was given CHOP (I) (cyclophos-
phamide 1500 mg on D1, doxorubicin 100 mg
on D1, vincristine 2 mg on D1, and prednisolone
100 mg/day on D1–D5) on April 30, 2004 and
CHOP (II) on May 17, 2004. The two courses of
chemotherapy were complicated with febrile neu-
tropenia, spontaneous bacterial peritonitis, and
Pseudomonas aeruginosa related sepsis. The infec-
tion episodes subsided under granulocyte-colony
stimulating factor and adequate antibiotics. Cytol-
ogy showed remarkable reduction of lymphoma
cells in ascites after the therapy. Intraperitoneal
injection of Picibanil (OK-432) (10KE every
Monday and Thursday since May 31, 2004 for a
total of six times) was given. CHOP (III) and
CHOP (IV) were given on June 17, 2004 and on
July 14, 2004. Again, the chemotherapy was com-
plicated by spontaneous bacterial peritonitis and
sepsis. The follow-up cytology of ascites was neg-
ative. Unfortunately, the cytology of ascites became
positive 1 month later.
The patient was admitted again in September
2004 for spontaneous bacterial peritonitis. Blood
culture yielded Enterobacter cloacae. However, the
liver function progressively deteriorated with ALT
elevated to 234 U/L, bilirubin 3.62 mg/dL and
prothrombin time 18.4 seconds (control, 12.9
seconds). HBV DNA level was 9274 pg/mL. YIDD
mutation was detected. Adefovir was added. How-
ever, the liver function deteriorated rapidly, re-
sulting in hepatic encephalopathy and hepatorenal
syndrome. The patient died of sepsis and hepatic
failure.
Discussion
PEL typically involves only one body cavity. It is
rare that both pleural and abdominal cavities are
involved, as in our case. Though the original de-
scription of PEL is a rare form of NHL which only
involves the body cavities in the absence of lym-
phadenopathy or organomegaly,1,2 it has recently
PCR for HHV-8
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Figure 2. Genomic human herpesvirus-8 (HHV-8) de-
tected in primary effusion lymphoma by polymerase 
chain reaction amplification method (primer 1: 5′GTTCT-
GCCAGGCATAGTC; primer 2: 5′AATAAGTATCCGACCY-
CAT). M = marker; lanes 1 and 2, pleural effusion (in
duplication); lanes 3 and 4, ascites (in duplication); lane 5,
positive control of HHV-8; lane 6, negative control.
been argued that Kaposi’s sarcoma-associated
herpes virus/HHV-8-positive solid lymphomas
could be a tissue-based variant of PEL.7 In con-
trast, not all lymphomas localized to the body
cavities are PELs. Burkitt’s lymphoma, pyothorax-
associated lymphoma, anaplastic large cell lym-
phoma and lymphomatous effusion secondary
to gastrointestinal tract lymphoma3,8–10 might also
present with lymphoma in the body cavities. To
make the diagnosis of PEL, it is important to rule
out these possibilities. In our case, we had care-
fully excluded these possibilities by endoscopic,
surgical and imaging studies.
The lymphoma cells of PEL exhibit variable
polymorphism, from large immunoblastic or plas-
mablastic cells to anaplastic cells. Nuclei are large
and round with prominent nucleoli. The cyto-
plasm is abundant and deeply basophilic with
clear vacuoles occasionally. The cells express leuko-
cyte common antigen (CD45) but are usually
negative for pan-B-cell and pan-T-cell markers.1
Activation and plasma cell-related markers such
as CD30, CD38 and CD138 are usually demon-
strated.11 The lymphoma cells in our case were
positive for CD138 and negative for CD19 and
CD3 by flow cytometry. This phenotype is incon-
sistent with the typical presentation of PEL cells.
In Carbone et al’s study, the expression of MUM-1/
IRF4 (multiple myeloma 1/interferon regulatory
factor 4) in PELs is 100%, strongly implicating its
role in the disease pathogenesis.12 Immunohis-
tologically, the lymphoma cells in the ascites of this
case were negative for MUM-1/IRF4, but the lym-
phoma cells in the pleural effusion were positive
for MUM-1/IRF4. This paradoxical finding might
be caused by the small number of lymphoma
cells in the second paracentesis.
Epidemiologically, the majority of PELs arise
in the setting of HIV infection. Most patients are
young to middle aged homosexual males.1 The
disease also occurs in the absence of HIV infection.
HIV-seronegative patients with PEL might have
an underlying immunodeficiency due to advanced
age or associated conditions such as cirrhosis or
cancer, or come from areas with high prevalence
of HHV-8 infection such as the Mediterranean.13,14
Failure to detect HHV-8 DNA sequences precludes
a diagnosis of PEL, although there were a few cases
of HHV-8 negative PEL reported.1,15,16
In Taiwan, the infection rate of HHV-8 is 19.2%
between the ages of 21 and 40.17 The HHV-8-
infected population rarely presents diseases ex-
cept in the group of patients of old age, AIDS,
cancer or impaired immunity. Although there are
several peritoneal PELs reported in association
with HCV-related liver cirrhosis,5,6 no PELs as-
sociated with HBV-related liver cirrhosis have
been reported. The HBV-related cirrhosis proba-
bly played the role of impairing immunity in our
patient. However, we need more cases to clarify
the role of HBV in PEL.
The treatment of PEL is not well established
because of small case numbers. Generally, the
prognosis is extremely unfavorable even with high-
dose chemotherapy and autologous stem cell 
reinfusion.18,19 Some case reports show complete
remission of PEL in HIV-seropositive patients after
antiviral therapy.20 An HIV-seronegative patient
who achieved durable remission has been re-
ported.21 Our patient, like in typical PEL, did 
not achieve durable remission and died within 
6 months of diagnosis. Thus, whether chemother-
apy is the treatment of choice in PEL needs to be
established. Targeting HHV-8 is a new idea of
treatment but it has not entered clinical trials.22,23
It is not surprising that YMDD mutant devel-
oped in our patient because lamivudine was used
for more than 1 year.24 However, the liver func-
tion deteriorated rapidly even when he was started
on adefovir.25 The course of our patient was more
fulminant than that in most patients with YMDD
mutants. One of the possible explanations was
that our patient was immunocompromised re-
lated to PEL, leading to unchecked HBV replica-
tion and final hepatic failure even with the use 
of adefovir.
In conclusion, when cirrhotic patients rap-
idly develop ascites, non-hepatic origins should 
also be considered in addition to liver cirrhosis
per se. Among the non-hepatic origins, the differ-
ential diagnosis should include PEL. Once PEL 
is diagnosed, the treatment should be carefully
PEL in HBV-LC
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considered. Novel therapy may be better than
conventional chemotherapy.
Acknowledgments
This study was supported by grants from the
Liver Disease Prevention and Treatment Research
Foundation, Taiwan.
References
1. Nador RG, Cesarman E, Chadburn A, et al. Primary effu-
sion lymphoma: a distinct clinicopathologic entity associ-
ated with the Kaposi’s sarcoma-associated herpesvirus.
Blood 1996;88:645–56.
2. Boulanger E, Agbalika F, Maarek O, et al. A clinical, mo-
lecular and cytogenetic study of 12 cases of human her-
pesvirus 8 associated with primary effusion lymphoma in
HIV-infected patients. Hematol J 2001;2:172–9.
3. Ely SA, Powers J, Lewis D, et al. Kaposi’s sarcoma-associated
herpes virus-positive primary effusion lymphoma arising
in the subarachnoid space. Hum Pathol 1999;30:981–4.
4. Klepfish A, Sarid R, Shtalrid M, et al. Primary effusion
lymphoma (PEL) in HIV-negative patients—a distinct clin-
ical entity. Leuk Lymphoma 2001;41:439–43.
5. Ascoli V, Lo Coco F, Artini M, et al. Primary effusion
Burkitt’s lymphoma with t(8;22) in a patient with hepatitis
C virus-related cirrhosis. Hum Pathol 1997;28:101–4.
6. Paner GP, Jensen J, Foreman KE, et al. HIV and HHV-8
negative primary effusion lymphoma in a patient with
hepatitis C virus-related liver cirrhosis. Leuk Lymphoma
2003;44:1811–4.
7. Carbone A, Gloghini A, Vaccher E, et al. Kaposi’s sarcoma-
associated herpesvirus/human herpesvirus type 8-positive
solid lymphomas: a tissue-based variant of primary effusion
lymphoma. J Mol Diagn 2005;7:17–27.
8. Iuchi K, Ichimiya A, Akashi A, et al. Non-Hodgkin’s lym-
phoma of the pleural cavity developing from long-standing
pyothorax. Cancer 1987;60:1771–5.
9. DePond W, Said JW, Tasaka T, et al. Kaposi’s sarcoma-
associated herpesvirus and human herpesvirus 8 (KSHV/
HHV8)-associated lymphoma of the bowel. Report of 
two cases in HIV-positive men with secondary effusion
lymphomas. Am J Surg Pathol 1997;21:719–24.
10. Chan AC, Chan JK, Yan KW, et al. Anaplastic large cell
lymphoma presenting as a pleural effusion and mimicking
primary effusion lymphoma. A report of 2 cases. Acta
Cytol 2003;47:809–16.
11. Gaidano G, Gloghini A, Gattei V, et al. Association 
of Kaposi’s sarcoma-associated herpesvirus-positive primary
effusion lymphoma with expression of the CD138/
syndecan-1 antigen. Blood 1997;90:4894–900.
12. Carbone A, Gloghini A, Cozzi MR, et al. Expression of
MUM1/IRF4 selectively clusters with primary effusion
lymphoma among lymphomatous effusions: implications
for disease histogenesis and pathogenesis. Br J Haematol
2000;111:247–57.
13. Teruya-Feldstein J, Zauber P, Setsuda JE, et al. Expression
of human herpesvirus-8 oncogene and cytokine homo-
logues in an HIV-seronegative patient with multicentric
Castleman’s disease and primary effusion lymphoma. 
Lab Invest 1998;78:1637–42.
14. Boulanger E, Hermine O, Fermand JP, et al. Human her-
pesvirus 8 (HHV-8)-associated peritoneal primary effusion
lymphoma (PEL) in two HIV-negative elderly patients. 
Am J Hematol 2004;76:88–91.
15. Ascoli V, Lo-Coco F. Body cavity lymphoma. Curr Opin
Pulm Med 2002;8:317–22.
16. Nakamura Y, Tajima F, Omura H, et al. Primary effusion
lymphoma of the left scrotum. Intern Med 2003;42:
351–3.
17. Huang LM, Huang SY, Chen MY, et al. Geographical differ-
ences in human herpesvirus 8 seroepidemiology: a survey
of 1,201 individuals in Asia. J Med Virol 2000;60:290–3.
18. Waddington TW, Aboulafia DM. Failure to eradicate
AIDS-associated primary effusion lymphoma with high-
dose chemotherapy and autologous stem cell reinfusion:
case report and literature review. AIDS Patient Care STDS
2004;18:67–73.
19. Boulanger E, Daniel MT, Agbalika F, et al. Combined
chemotherapy including high-dose methotrexate in KSHV/
HHV8-associated primary effusion lymphoma. Am J
Hematol 2003;73:143–8.
20. Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-
induced apoptosis in primary effusion lymphoma through
azidothymidine-mediated inhibition of NF-kappa B. Blood
2003;101:2321–7.
21. Inoue Y, Tsukasaki K, Nagai K, et al. Durable remission by
sobuzoxane in an HIV-seronegative patient with human
herpesvirus 8-negative primary effusion lymphoma. Int J
Hematol 2004;79:271–5.
22. Klass CM, Offermann MK. Targeting human herpesvirus-
8 for treatment of Kaposi’s sarcoma and primary effusion
lymphoma. Curr Opin Oncol 2005;17:447–55.
23. Cannon M, Cesarman E, Boshoff C. KSHV G protein-
coupled receptor inhibits lytic gene transcription in primary-
effusion lymphoma cells via p21-mediated inhibition of
Cdk2. Blood 2006;107:277–84.
24. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as ini-
tial treatment for chronic hepatitis B in the United States.
N Engl J Med 1999;341:1256–63.
25. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-
negative chronic hepatitis B. N Engl J Med 2003;348:
800–7.
P.Y. Hsieh, et al
508 J Formos Med Assoc | 2007 • Vol 106 • No 6
